Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) - Business Wire

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), card

By: Business Wire

Oct 08 2024
0
0 Views

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di… [+15026 chars]

Butterfly Equity is taking luxury wine maker Duckhorn private in $1.95 billion all-cash deal - MarketWatch

I went to SF's buzzy $25 all-you-can-eat restaurant and was publicly scolded - SFGATE

U.S. crude oil jumps 2%, trades near $76 as market waits for Israel strike against Iran - CNBC

Gold Steadies as Expectations of Federal Reserve Rate Cut Fade - Yahoo Finance

Costco’s Gold Bars Fly Off Shelves as Bullion Prices Smash Records - Yahoo Finance

Tesla Model 2 unveiling predictions for the Robotaxi event - TESLARATI

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network